Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...

Generalized Anxiety Disorder Treatment Market Size is estimated to reach US$ 4261.25 Million by 2033, growing at a CAGR of 9% during the forecast period 2023 to 2033 | Future Market Insights, Inc. NEWARK, Del, March 29, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Generalized anxiety disorder treatment market is expected to grow at a value of 9% CAGR, according to...

Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...

Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary...

Antidepressant Drugs Market to Grow Valuation of $15.98 Billion by 2023 Portland, OR, Aug. 06, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research,the antidepressant drugs market accounted for $13.75 billion in 2016, and is estimated to...